Board of Directors
The chart below describes the structure of the committees under Novavax' Board of Directors.
|Audit Committee||Compensation Committee||Nominating & Corporate Governance Committee||Finance Committee|
|James F. Young||Chairman||X|
|Stanley C. Erck||X|
|Gary C. Evans||X||Chairman||Chairman|
|John O. Marsh, Jr.||X||X|
|Michael A. McManus, Jr.||Chairman||X||X||X|
James F. Young, Ph.D.
Dr. Young joined Novavax' Board of Directors in April 2010 and was appointed Chairman in April 2011. He has over 30 years of experience in the fields of molecular genetics, microbiology, immunology and pharmaceutical development. Most recently, Dr. Young was MedImmune's President of Research and Development, where he had responsibility for regulatory affairs and was instrumental in the development of FluMist® and Synagis®. In 2005, Dr. Young was awarded the Albert B. Sabin Humanitarian Award. Prior to MedImmune, Dr. Young was influential in building the department of molecular genetics at Smith Kline & French Laboratories (now part of GlaxoSmithKline) and culminated as director, department of molecular genetics. Dr. Young was on the faculty of the department of microbiology at Mount Sinai School of Medicine in New York, NY. He received his doctorate in microbiology and immunology from Baylor College of Medicine in Houston, Texas and Bachelor of Science degrees in biology and general sciences from Villanova University.
Stanley C. Erck
Mr. Erck was named President & Chief Executive Officer of Novavax in April 2011. He became a Novavax Director in June 2009 and beginning in February 2010, served as its Executive Chairman of the Board. From 2000 to 2008, Mr. Erck was President and Chief Executive Officer of Iomai Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Prior to Iomai, Mr. Erck served as President and Chief Executive Officer of Procept, a publicly traded immunology company; as Vice President, Corporate Development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the Board of Directors of BioCryst Pharmaceuticals, MaxCyte, Inc. and the MdBio Foundation. He received his undergraduate degree from the University of Illinois and his Masters in Business Administration from the University of Chicago Graduate School of Business.
Richard Douglas, Ph.D.
Dr. Douglas joined the Novavax Board in 2010. He has over 25 years of biotechnology experience having previously served in Corporate Development roles at Genzyme Corporation since 1989. Most recently, Dr. Douglas was Senior Vice President Corporate Development and a Corporate Officer of Genzyme Corporation. As a leader of Genzyme's Corporate Development team, Dr. Douglas was involved in numerous acquisitions, licenses, joint ventures and strategic alliances. From 1982 till its merger with Genzyme Corporation in 1989, Dr. Douglas served in Science and Corporate Development capacities at Integrated Genetics. Dr. Douglas was a postdoctoral fellow in Leroy Hood's laboratory at the California Institute of Technology. He received a Ph.D. from the University of California, Berkeley in biochemistry and a B.S. in chemistry from the University of Michigan. He currently serves on the University of Michigan Technology Transfer National Advisory Board.
Gary C. Evans
Mr. Evans joined the Novavax Board in 1998, and served as Lead Independent Director from April 2007 until April 2011 and Chairman from April 2005 until March 2007. He has been Chairman and Chief Executive Officer of Magnum Hunter Resources Corporation, a NYSE Amex listed oil and gas company, since May 2009 and has been Chairman, President, Chief Executive Officer and Founder of GreenHunter Energy, Inc., a NYSE Amex listed alternative energy company, since 2007. He was Chairman of the Board of Directors and Chief Executive Officer of its predecessor, Hunter Resources, Inc., from 1985 to 1995. Mr. Evans is currently a trustee of TEL Offshore Trust, a NASDAQ listed oil and gas trust and a Board member of Global Hunter Securities, LLC since 2005. Mr. Evans is a serial entrepreneur, having founded, grown and provided successful exit strategies for several companies and is highly skilled in capital raising activities. He was recognized by Ernst & Young as the Southwest Area 2004 Entrepreneur of the Year for the Energy Sector and was recently inducted into the World Hall of Fame for Ernst & Young Entrepreneurs.
John O. Marsh, Jr.
Mr. Marsh joined the Novavax Board of Directors in 1991 (then known as Molecular Packaging Systems, Inc.) and served as Interim Chief Executive Officer from July 1996 to March 1997 and as Chairman of the Board from July 1996 to February 1997. He is currently the Distinguished Adjunct Professor of Law at George Mason University and has been Co-Chair of the Independent Review Group for Walter Reed Hospital and the Bethesda Navy Medical Center since 2007. He also has served as Visiting Professor of Ethics at Virginia Military Institute in 1998. Mr. Marsh was Secretary of the Army from 1981 to 1989, a Counselor with Cabinet rank to the President of the United States from 1974 to 1977, Assistant for National Security Affairs to Vice President of the United States in 1974, and Assistant Secretary of Defense from 1973 to 1974. Mr. Marsh was a U.S. Representative in Congress from 1963 to 1971. He has been awarded the Department of Defense Distinguished Public Service Award on six occasions and was awarded the Presidential Citizens Medal from President Ronald Reagan.
Michael A. McManus, Jr.
Mr. McManus joined the Novavax Board in 1998. He has served as President, Chief Executive Officer and Director of Misonix, Inc., a medical, scientific and industrial provider of ultrasonic and air pollution systems, since 1998. Previously, he was President and Chief Executive Officer of NewYork Bancorp Inc. from 1991 to 1998. From 1990 through November 1991, Mr. McManus was President and Chief Executive Officer of Jamcor Pharmaceuticals Inc. Mr. McManus served as an Assistant to the President of the United States from 1982 to 1985 and held positions with Pfizer Inc. and Revlon Group. Mr. McManus received a B.A. in economics from the University of Notre Dame and a J.D. from the Georgetown University Law Center. He served in the U.S. Army Infantry from 1968 through 1970. Mr. McManus currently serves as a member of the Board of Directors of A. Schulman Inc. He is also a recipient of the Ellis Island Medal of Honor.
Rajiv I. Modi, Ph.D.
Dr. Modi joined Novavax' Board in April 2009 and represents Satellite Overseas (Holdings) Limited, one of Novavax' largest shareholders. He has been the Managing Director of Cadila Pharmaceuticals. Ltd., a company organized in India, since 1995 and is Director of other Cadila Group companies. Dr. Modi holds a Ph.D. in Biological Science from the University of Michigan, Ann Arbor, USA. He obtained his M.Sc. in Biochemical Engineering from Indian Institute of Technology (IIT), Bombay, India. Dr. Modi is the winner of the Genetic Society of America's Best Scientific Poster at the International Genetics Congress held in August 1988 by the Genetic Society of America. He has presented many papers on various aspects of Chemical Engineering, Biochemical Engineering and Biotechnology at many institutes in India and abroad and is a member of many prestigious organizations and associations.